UY37777A - Combinación de un inhibidor de mcl-1 y un tratamiento de atención estándar para cánceres hematológico, usos y composiciones farmacéuticas de esta - Google Patents

Combinación de un inhibidor de mcl-1 y un tratamiento de atención estándar para cánceres hematológico, usos y composiciones farmacéuticas de esta

Info

Publication number
UY37777A
UY37777A UY0001037777A UY37777A UY37777A UY 37777 A UY37777 A UY 37777A UY 0001037777 A UY0001037777 A UY 0001037777A UY 37777 A UY37777 A UY 37777A UY 37777 A UY37777 A UY 37777A
Authority
UY
Uruguay
Prior art keywords
mcl
inhibitor
combination
pharmaceutical compositions
care treatment
Prior art date
Application number
UY0001037777A
Other languages
English (en)
Inventor
Leticia Maragno Ana
Olivier Geneste
Andrew Wei
Donia Moujalled
Giovanna Pomilio
Original Assignee
Servier Lab
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Servier Lab, Novartis Ag filed Critical Servier Lab
Publication of UY37777A publication Critical patent/UY37777A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Una combinación que comprende un inhibidor de Mcl-1 y un segundo agente anticanceroso, en la que el segundo agente anticanceroso se selecciona de antraciclinas, citarabina y agentes hipometilantes, y composiciones y usos de esta.
UY0001037777A 2017-06-22 2018-06-21 Combinación de un inhibidor de mcl-1 y un tratamiento de atención estándar para cánceres hematológico, usos y composiciones farmacéuticas de esta UY37777A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762523389P 2017-06-22 2017-06-22
EP17189550 2017-09-06

Publications (1)

Publication Number Publication Date
UY37777A true UY37777A (es) 2019-01-31

Family

ID=62631122

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001037777A UY37777A (es) 2017-06-22 2018-06-21 Combinación de un inhibidor de mcl-1 y un tratamiento de atención estándar para cánceres hematológico, usos y composiciones farmacéuticas de esta

Country Status (26)

Country Link
US (1) US11466023B2 (es)
EP (1) EP3641775B1 (es)
JP (1) JP7186731B2 (es)
KR (1) KR20200018681A (es)
CN (2) CN111032050B (es)
AR (1) AR112202A1 (es)
AU (1) AU2018288520B2 (es)
BR (1) BR112019026959A2 (es)
CA (1) CA3068096C (es)
CL (1) CL2019003763A1 (es)
CO (1) CO2019014479A2 (es)
CU (1) CU20190105A7 (es)
EA (1) EA202090082A1 (es)
ES (1) ES2971466T3 (es)
GE (1) GEP20227357B (es)
IL (1) IL271475B2 (es)
JO (1) JOP20190287A1 (es)
MA (1) MA49444A (es)
NI (1) NI201900128A (es)
PH (1) PH12019502789A1 (es)
SG (1) SG11201911891WA (es)
TW (1) TWI753178B (es)
UA (1) UA126920C2 (es)
UY (1) UY37777A (es)
WO (1) WO2018234433A1 (es)
ZA (1) ZA201908446B (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3222752A1 (en) 2021-06-11 2022-12-15 Gilead Sciences, Inc. Combination mcl-1 inhibitors with anti-body drug conjugates
TW202315637A (zh) 2021-06-11 2023-04-16 美商基利科學股份有限公司 Mcl-1抑制劑與抗癌劑之組合

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2504611A1 (en) 2002-11-06 2004-05-27 Wyeth Combination therapy for the treatment of acute leukemia and myelodysplastic syndrome
JP5731986B2 (ja) 2008-12-09 2015-06-10 ダナ ファーバー キャンサー インスティテュート インコーポレイテッド Ｍｃｌ−１の特異的調節の方法及び組成物
ES2602475T3 (es) * 2010-04-15 2017-02-21 Tracon Pharmaceuticals, Inc. Potenciación de la actividad anticáncer por terapia de combinación con inhibidores de la vía BER
CA2712747A1 (en) * 2010-08-11 2012-02-11 Universite De Montreal Combinatory cancer treatment
FR3015483B1 (fr) 2013-12-23 2016-01-01 Servier Lab Nouveaux derives de thienopyrimidine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
EP3154590B1 (en) * 2014-06-13 2021-04-14 Calithera Biosciences, Inc. Combination therapy with glutaminase inhibitors
FR3037956B1 (fr) 2015-06-23 2017-08-04 Servier Lab Nouveaux derives d'acide amine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR3037957B1 (fr) * 2015-06-23 2019-01-25 Les Laboratoires Servier Nouveaux derives d'hydroxyester, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR3037959B1 (fr) 2015-06-23 2017-08-04 Servier Lab Nouveaux derives bicycliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR3037958B1 (fr) * 2015-06-23 2019-01-25 Les Laboratoires Servier Nouveaux derives d'hydroxy-acide, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR3046792B1 (fr) 2016-01-19 2018-02-02 Les Laboratoires Servier Nouveaux derives d'ammonium, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
WO2018236904A1 (en) * 2017-06-19 2018-12-27 Surface Oncology, Inc. COMBINATION OF ANTI-CD47 ANTIBODIES AND CELL DEATH INDUCING AGENTS, AND USES THEREOF

Also Published As

Publication number Publication date
WO2018234433A1 (en) 2018-12-27
CN117959451A (zh) 2024-05-03
RU2020101626A (ru) 2021-07-22
JOP20190287A1 (ar) 2019-12-16
PH12019502789A1 (en) 2020-09-14
IL271475B2 (en) 2023-09-01
US20200392151A1 (en) 2020-12-17
JP7186731B2 (ja) 2022-12-09
IL271475B1 (en) 2023-05-01
CA3068096A1 (en) 2018-12-27
EP3641775A1 (en) 2020-04-29
US11466023B2 (en) 2022-10-11
RU2020101626A3 (es) 2021-10-05
GEP20227357B (en) 2022-02-25
ZA201908446B (en) 2023-10-25
CO2019014479A2 (es) 2020-02-28
CL2019003763A1 (es) 2020-06-19
BR112019026959A2 (pt) 2020-07-07
AR112202A1 (es) 2019-10-02
EP3641775B1 (en) 2023-12-06
IL271475A (en) 2020-01-30
MA49444A (fr) 2020-04-29
SG11201911891WA (en) 2020-01-30
CN111032050B (zh) 2024-01-19
TWI753178B (zh) 2022-01-21
AU2018288520B2 (en) 2024-05-30
UA126920C2 (uk) 2023-02-22
NI201900128A (es) 2020-03-30
CN111032050A (zh) 2020-04-17
CA3068096C (en) 2022-10-04
CU20190105A7 (es) 2020-10-20
EA202090082A1 (ru) 2020-05-22
KR20200018681A (ko) 2020-02-19
TW201904579A (zh) 2019-02-01
ES2971466T3 (es) 2024-06-05
JP2020524681A (ja) 2020-08-20
AU2018288520A1 (en) 2020-01-16

Similar Documents

Publication Publication Date Title
SV2018005778A (es) Derivados aromaticos de sulfonamida
SV2017005461A (es) Benzamidas sustituidas con 1,3-tiazol-2-ilo
CL2020001312A1 (es) Composiciones de cannabidiol y usos de las mismas. (divisional solicitud 201803425).
UY37952A (es) Formulaciones de un inhibidor de la quinasa trk macrocíclica
CL2018001557A1 (es) Uso de un agente inhibidor de masp-2 que inhibe la activación del complemento dependiente de masp-2, para tratar un sujeto que padece de síndrome antifosfolipido catastrófico (safc). (solicitud divisional 201600908)
CO2017001994A2 (es) Compuestos activos hacia bromodominios
CL2017002335A1 (es) Composiciones de cosmetica topica para combatir radicales libres
BR112018008601A2 (pt) composições compreendendo o canabidiol e segundos agentes terapêuticos para o tratamento de câncer
CR20170356A (es) Composiciones farmacéuticas para terapia combinada
CL2017002214A1 (es) Formulación de combinación de tesofensina y betabloqueante
BR112018002520A2 (pt) Agonistas de tlr4 e composições dos mesmos e seuuso no tratamento de câncer
NI201900128A (es) Combinación de un inhibidor de mcl-1 y un tratamiento de atención estándar para cáncer hematológico, usos y composiciones farmacéuticas de esta
CO2019002245A2 (es) Combinación de agonistas de fxr
UY37560A (es) Combinación de un inhibidor de mcl-1 y un compuesto taxano, usos y composiciones farmacéuticas de ésta
UY37342A (es) Combinación de un inhibidor de bcl-2 y un inhibidor de mcl1, usos y composiciones farmacéuticas de éstos
CL2019002514A1 (es) Composiciones cosméticas para el cuidado de la piel.
BR112021000279A8 (pt) formulações de redução de tumor e métodos de uso das mesmas
ECSP19006687A (es) Combinación de un inhibidor de bcl-2 y un inhibidor de mcl-1, usos y composiciones farmacéuticas de éstos
BR112019000706A2 (pt) agente de estímulo do receptor 1b de 5-hidroxitriptamina para reparo de pele e/ou cabelo
BR112018067453A2 (pt) combinações de glicoalcaloide e vários usos da mesma
CO2017001076A2 (es) Composiciones farmacéuticas antihiperalgésicas, antialodínicas y antiinflamatorias que contienen pregabalina y meloxicam
UY38319A (es) Composición farmacéutica para el tratamiento de la adicción a sustancias psicoactivas y/o para la prevención de las recaídas a dicha adicción
CL2018003338A1 (es) Formulaciones inyectables fisiológicamente balanceadas de fosnetupitant.
CL2019003288A1 (es) Una combinación farmacéutica para el tratamiento de un cáncer.
CO2019007261A2 (es) Combinación de un inhibidor de mcl-1 y un compuesto taxano, usos y composiciones farmacéuticas de ésta